Top

Journal of Mammary Gland Biology and Neoplasia

Published in:

01-10-2005 | Review Article

Benign Breast Diseases

Authors: Carine Courtillot, Geneviève Plu-Bureau, Nadine Binart, Corinne Balleyguier, Brigitte Sigal-Zafrani, Vincent Goffin, Frédérique Kuttenn, Paul A. Kelly, Philippe Touraine

Published in: Journal of Mammary Gland Biology and Neoplasia | Issue 4/2005

Abstract

Benign breast diseases have always been neglected in comparison to cancer, despite the fact that there are many more patients with such diseases than patients presenting to a breast clinic for cancer. Like normal breast tissues, benign breast diseases are under a complex system of controls by both systemic hormonal and local factors. In this review, we attempt to present an overview of the latest knowledge concerning the epidemiology, classification, clinical presentation, management, and physiopathology of these disorders.

Sitruk-Ware R, Plu-Bureau G. Epidemiology and treatment of benign breast disease: effect of progestins on breast disease. In: Sitruk-Ware R, Mishelle DR Jr., Editors. Progestins and antiprogestins in clinical practice. New-York: Marcel Dekker; 2000. pp. 327–40.

Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146–51.PubMedCrossRef

Hughes LE, Mansel RE, Webster DJT. Aberrations of normal development and involution (ANDI): a new perspective on pathogenesis and nomenclature of benign breast disorders. Lancet 1987;2:1316–9.PubMedCrossRef

Plu-Bureau G, Thalabard JC, Sitruk-Ware R, Asselain B, Mauvais-Jarvis P. Cyclical mastalgia as a marker of breast cancer susceptibility: results of a case-control study among French women. Br J Cancer 1992;65:945–9.PubMed

Goodwin PJ, DeBoer G, Clark RM, Catton P, Redwood S, Hood N, Boyd NF. Cyclical mastopathy and premenopausal breast cancer risk. Results of a case-control study. Breast Cancer Res Treat 1995;33:63–73.PubMedCrossRef

Goehring C, Morabia A. Epidemiology of benign breast disease, with special attention to histologic types. Epidemiol Rev 1997;19:310–27.PubMed

Hughes LE, Mansel RE, Webster DJT. Benign disorders and diseases of the breast—concepts and clinical management. 2nd ed. W.B. Saunders; 2000. Chap. 2, pp. 7–20.

Parks AG. The microanatomy of the breast. Ann R Coll Surg Engl 1959;25:295–311.

Noguchi S, Yokouchi H, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H. Progression of fibroadenoma to phyllodes tumor demonstrated by clonal analysis. Cancer 1995;76:1779–85.PubMedCrossRef

10.

Hughes LE, Mansel RE, Webster DJT. Benign disorders and diseases of the breast—concepts and clinical management. 2nd ed. W.B. Saunders; 2000. Chap. 3, pp. 21–34.

11.

La Rosa S, Sessa F, Colombo L, Tibiletti MG, Furlan D, Capella C. Expression of acidic fibroblast growth factor (aFGF) and fibroblast growth factor receptor 4 (FGFR4) in breast fibroadenomas. J Clin Pathol 2001;54:37–41.PubMedCrossRef

12.

Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD Jr, Rados MS, Schuyler PA. Long term risk of breast cancer in women with fibroadenoma. New Engl J Med 1994;331:10–15.PubMedCrossRef

13.

Hughes LE, Mansel RE, Webster DJT. Benign disorders and diseases of the breast—concepts and clinical management. 2nd ed. W.B. Saunders; 2000. Chap. 7, pp. 73–94.

14.

Cole-Beuglet C, Soriano RZ, Kurtz AB, Goldberg BB. Fibroadenoma of the breast. Sonomammography correlated with pathology in 122 patients. American Journal of Radiology 1983;140:369–75.

15.

Mauvais-Jarvis P. Le traitement hormonal des mastopathies bénignes. Bull Cancer 1991;78:365–71.PubMed

16.

Kumar S, Mansel RE, Hughes LE, Edwards CA, Scanlon MF. Prediction of response to endocrine therapy in pronounced cyclical mastalgia, using dynamic tests of prolactin release. Clin Endocrinol 1985;23:699–704.CrossRef

17.

Hughes LE, Mansel RE, Webster DJT. Benign disorders and diseases of the breast—concepts and clinical management. 2nd ed. W.B. Saunders; 2000. Chap. 9, pp. 123–35.

18.

Hughes LE, Mansel RE, Webster DJT. Benign disorders and diseases of the breast—concepts and clinical management. 2nd ed. W.B. Saunders; 2000. Chap. 6, pp. 61–72.

19.

Cowen PN, Benson EA. Cytological study of fluid from benign breast cysts. Br J Surg 1979;66:209–11.PubMedCrossRef

20.

Angeli A, Bradlow HL, Chasalon FI, Dogliotti L. Biochemistry of breast cyst fluid. Ann N Y Acad Sci 1990;586:1–296.CrossRef

21.

Hughes LE, Mansel RE, Webster DJT. Benign disorders and diseases of the breast—concepts and clinical management. W.B. Saunders, 2d ed., 2000; chap. 4, pp 35–47.

22.

De Boever J, Vandekerckhove D. Benign breast disease: steroid concentrations. J Steroid Biochem 1982;Abst 338.

23.

Wang DY, Fentiman IS. Epidemiology and endocrinology of benign breast disease. Breast Cancer Res Treat 1985;6:5–39.PubMedCrossRef

24.

Pasqualini JR, Chetrite G. Activity and regulation of sulfatase, sulfotransferase and 17β-hydroxysteroid dehydrogenase in breast cancer. In: Pasqualini JR, Katzenellenbogen BS, Editors. Hormone-dependent cancer. New York: Marcel Dekker; 1996. pp. 21–80.

25.

Pasqualini JR, Cortes-Prieto J, Chetrite G, Talbi M, Ruiz A. Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma. Int J Cancer 1997;70:639–43.PubMedCrossRef

26.

Martin PM, Kuttenn F, Serment H, Mauvais-Jarvis P. Studies on clinical, hormonal and pathological correlations in breast fibroadenomas. J Steroid Biochem 1978;9:1251–55.PubMedCrossRef

27.

Tseng L, Gusberg SB, Gurpide E. Estradiol receptor and 17β-hydroxysteroid dehydrogenase in normal and abnormal human endometrium. Ann N Y Acad Sci 1977;286:190–8.PubMedCrossRef

28.

Allegra JC, Lippman ME, Green L, Barlock A, Simon R, Thompson EB, Huff KK, Griffin W. Estrogen receptor values in patients with benign breast disease. Cancer 1979;44:228–31.PubMedCrossRef

29.

Martin PM, Kuttenn F, Serment H, Mauvais-Jarvis P. Progesterone receptors in breast fibroadenomas. J Steroid Bioch 1979;11:1295–98.CrossRef

30.

Kuttenn F, Fournier S, Durand JC, Mauvais-Jarvis P. Estradiol and progesterone receptors in human breast fibroadenomas. J Clin Endocrinol Metab 1981;52:1225–9.PubMedCrossRef

31.

Ferrieres C, Cuny M, Simony-Fontaine J. Variation of Bcl-2 expression in breast ducts and lobules in relation to plasma progesterone levels: overexpression and absence of variation in fibroadenomas. J Pathol 1997;183:204–11.PubMedCrossRef

32.

Mauvais-Jarvis P, Sitruk-Ware R, Kuttenn F, Sterkers N. Luteal phase insufficiency: a common pathophysiologic factor in development of benign and malignant breast diseases. Comment Res Breast Dis 1979;1:25–59.

33.

England PC, Skinner LG, Cottrell KM, Sellwood RA. Sex hormones in breast disease. Br J Surg 1975;62:806–9.PubMedCrossRef

34.

Peters F, Pickardt CR, Zimmerman G, Breckwoldt M. PRL, TSH and thyroid hormones in benign breast disease. Klin Wochenschr 1981;59:403–7.PubMedCrossRef

35.

Kumar S, Mansel RE, Hughes LE, Woodhead JS, Edwards CA, Scanlon MF, Newcombe RG. Prolactin response to thyrotropin-releasing hormone stimulation and dopaminergic inhibition in benign breast disease. Cancer 1984;53:1311–5.PubMedCrossRef

36.

Gately CA, Maddox PR, Jones DL. Biologically active prolactin in patients with macroscopic breast cysts. Br J Surg 1992;79:1238.

37.

Ginsburg E, Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 1995;55:2591–5.PubMed

38.

Clevenger CV, Chang WP, Ngo W, Pasha TM, Montone KT, Tomaszewski JE. Expression of prolactin and prolactin receptor in human breast carcinoma. Am J Pathol 1995;146:695–705.PubMed

39.

Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 1997;138:5555–60.PubMedCrossRef

40.

Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, Nicolas A, Trivin C, Postel-Vinay MC, Kuttenn F, Kelly PA. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab 1998;83:667–74.PubMedCrossRef

41.

Clevenger CV, Plank TL. Prolactin as an autocrine/paracrine factor in breast cancer. J Mammary Gland Biol Neopl 1997;2:59–68.CrossRef

42.

Vonderhaar BK. Prolactin: the forgotten hormone of human breast cancer. Pharmacol Ther 1998;79:169–78.PubMedCrossRef

43.

Goffin V, Touraine P, Pichard C, Bernichtein S, Kelly PA. Should prolactin be reconsidered as a therapeutic target in human breast cancer? Mol Cell Endocrinol 1999;151:79–87.PubMedCrossRef

44.

Llovera M, Touraine P, Kelly PA, Goffin V. Involvement of prolactin in breast cancer: redefining the molecular targets. Exp Gerontol 2000;35:41–51.PubMedCrossRef

45.

Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003;24:1–27.PubMedCrossRef

46.

Manhes C, Kayser C, Bertheau P, Kelder B, Kopchick JJ, Kelly PA, Touraine P, Goffin V. Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but not carcinoma. J Endocrinol 2006;190:273–87.CrossRef

47.

Ryska A, Reynolds C, Keeney GL. Benign tumors of the breast with multinucleated stromal giant cells. Immunohistochemical analysis of six cases and review of the literature. Virchows Arch 2001;439:768–75.PubMed

48.

Mol JA, Henzen-Longmans SC, Hageman Ph, Misdorp W, Blankenstein MR, Rijnberk A. Expression of the gene encoding GH in the human mammary gland. J Clin Endocrinol Metab 1995;80:3094–6.PubMedCrossRef

49.

Ng ST, Zhou J, Adesanya OO, Wang J, LeRoith D, Bondy CA. Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nature Medicine 1997;10:1141–4.CrossRef

50.

Holdaway IM, Mason BH, Lethaby AE, Singh V, Harman JE, MacCormick M, Civil ID. Serum levels of insulin-like growth factor binding protein-3 in benign and malignant breast disease. Aust NZ J Surg 1999;69:495–500.CrossRef

51.

Cullen KJ, Smith HS, Hill S, Rosen N, Lippman ME. Growth factor messenger RNA expression by human breast fibroblasts, benign and malignant lesions. Cancer Res 1991;51:4978–85.PubMed

52.

Fantl V, Creer A, Dillon C, Bresnick J, Jackson D, Edwards P, Rosewell I, Dickson C. Fibroblast growth factor signaling and cyclin D1 function are necessary for normal mammary gland development during pregnancy. Advances in Experimental Medicine and Biology, vol. 480 “Biology of the mammary gland” 2000. Chap 1, pp. 1–7.

53.

Coombes RC, Gomm JJ, Luqmani YA. Acidic and basic FGF and their receptors in normal and malignant breast cells. Endocrinology 1994;35:259.

54.

Gomm JJ, Smith J, Ryall GK, Baillie R, Turnbull L, Coombes RC. Localization of basic fibroblast growth factor and transforming growth factor β1 in the human mammary gland. Cancer Res 1991;51:4685–92.PubMed

55.

Barraclough R, Fernig DG, Rudland PS, Smith JA. Synthesis of basic fibroblast growth factor upon differentiation of rat mammary epithelial to myoepithelial-like cells in culture. J Cell Physiol 1990;144:333–44.PubMedCrossRef

56.

Ethier SP, Van de Velde. Secretion of TGF-β like growth inhibitor by normal rat mammary epithelial cells. J Cell Physiol 1990;142:15–20.PubMedCrossRef

57.

Lippman ME, Dickson RB. Growth control of normal and malignant breast epithelium. Proc R Soc Edinburgh 1989;95b:89–106.

58.

Baillie R, Coombes RC, Smith J. Multiple forms of TGF-β1 in breast tissues: a biologically active form of the small latent complex of TGF-β1. European Journal of Cancer 1996;32A(9):1566–73.PubMedCrossRef

59.

Di Loreto C, Reis FM, Cataldi P, Zuiani C, Luisi S, Beltrami CA, Petraglia F. Human mammary gland and breast carcinoma contain immunoreactive inhibin/activins subunits: evidence for a secretion into cystic fluid. Eur J Endocrinol 1999;141:190–4.PubMedCrossRef

60.

Wang Y, Selden C, Morgan N, Stamp GWH, Hodgson HJF. Hepatocyte growth factor/scatter factor expression in human mammary epithelium. Am J Pathol 1994;144:675–82.PubMed

61.

Feakins RM, Wells CA, Young KA, Sheaff MT. Platelet-derived growth factor expression in phyllodes tumors and fibroadenomas of the breast. Hum Pathol 2000;31:1214–22.PubMedCrossRef

Title: Benign Breast Diseases
Authors: Carine Courtillot
Geneviève Plu-Bureau
Nadine Binart
Corinne Balleyguier
Brigitte Sigal-Zafrani
Vincent Goffin
Frédérique Kuttenn
Paul A. Kelly
Philippe Touraine
Publication date: 01-10-2005
Publisher: Springer US
Published in: Journal of Mammary Gland Biology and Neoplasia / Issue 4/2005
Print ISSN: 1083-3021
Electronic ISSN: 1573-7039
DOI: https://doi.org/10.1007/s10911-006-9006-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2005

Introduction on Angiogenesis in Breast Cancer

Multifaceted Role of Rho Proteins in Angiogenesis

The Role of Copper in Tumour Angiogenesis

Employing Tumor Hypoxia for Oncolytic Therapy in Breast Cancer

Non-Angiogenic Functions of VEGF in Breast Cancer

VEGF-Targeting Therapy for Breast Cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer